Cart
sales@molnova.com
BX-517
CAS No. 850717-64-5
BX-517( BX-517 | BX 517 | BX517 | PDK1 inhibitor2 )
Catalog No. M17615 CAS No. 850717-64-5
BX-517 is a potent and selective inhibitor of PDK1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 25MG | 147 | In Stock |
|
| 50MG | 269 | In Stock |
|
| 100MG | 423 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBX-517
-
NoteResearch use only, not for human use.
-
Brief DescriptionBX-517 is a potent and selective inhibitor of PDK1.
-
DescriptionBX-517, also known as PDK1 inhibitor2, is a potent and selective PDK1 inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsBX-517 | BX 517 | BX517 | PDK1 inhibitor2
-
PathwayMetabolic Enzyme/Protease
-
TargetRetinoid Receptor
-
RecptorPDK1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number850717-64-5
-
Formula Weight282.3
-
Molecular FormulaC15H14N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 27 mg/mL; 95.64 mM
-
SMILESO=C(Nc1cc2c(NC(=O)/C/2=C(\c2ccc[nH]2)/C)cc1)N
-
Chemical Name(Z)-N-(3-(1-(1H-pyrrol-2-yl)ethylidene)-2-hydroxy-3H-indol-5-yl)carbamimidic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Islam I, et al. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3819-25.
molnova catalog
related products
-
Isotretinoin
Isotretinoin(13-cis-Retinoic acid) is a medication used for the treatment of severe acne.
-
CD 1530
CD 1530 is a selective and potent RARγ agonist (Kd:150 nM) with potential anticancer activity, shows insecticidal activity against Cryptobacterium hidradii nematodes, and can be used to study oral carcinogenesis.
-
WYC209
WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs IC50: 0.19 uM). It targets the retinoic acid receptor (RAR).
